

A LEGACY OF **IMPACT**

MYLAN 2019 GLOBAL SOCIAL
RESPONSIBILITY REPORT SUMMARY



**Better Health
for a Better World®**

Our Mission

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.



Our Commitment to Global Social Responsibility

As Mylan has grown over time from a regional company to one that now serves patients in nearly every corner of the world, we have also expanded our commitment to social responsibility. It is a critical component of our operations and part of our overall focus of ensuring long-term, sustainable results and positive impact. We know well that our actions affect not only the communities we serve but also our ability to fulfill our mission to provide 7 billion people access to high quality medicine. From providing high quality medicine in more than 165 countries to finding ways to reduce our environmental impact, we are committed to helping lead positive change through social responsibility.



Mylan supports the 2030 Agenda for Sustainable Development, as articulated by the U.N., in the adoption of the Sustainable Development Goals (SDGs), by all member states in 2015. And we know that companies must play an active role for these goals to be achieved.

Good Health and Well-Being (Goal #3) is the goal where we can have our most significant positive impact. Our portfolio, footprint and our partnerships enable us to truly contribute to this goal.



As a global healthcare company, how we conduct ourselves and interact with our partners impacts other goals. Therefore, we work to ensure a safe, fair and inclusive workplace. We nurture a culture of integrity and uphold ethical business practices. We support local communities and work diligently to reduce our environmental impact. These efforts are all integral to delivering on our mission.

Our Vision for Global Social Responsibility

Global social responsibility is intrinsically woven within Mylan's commitment to achieve our mission and deliver better health for a better world. It is what drives our enduring passion to improve access and serve unmet needs across all geographies, while respecting the environment and positively impacting our stakeholders.



Our Commitment to Access

We believe every person matters and deserves the opportunity to live a healthy life. Throughout our history, Mylan's foundation and core business model have been focused on providing access to high quality medicine. Given the significance of patient needs across the globe and across all income levels, we are convinced that meeting this challenge requires a consistent and sustainable commitment.

Our definition of access is making sure the medicine we make is actually getting into the hands of patients in the more than 165 countries and territories we serve.

"If you have ever interacted with someone from Mylan, you know our mission is a cause that is deeply personal. Providing access to high quality medicine has been our purpose since the very beginning in 1961. Today, we are more committed than ever to our goal of creating better health for a better world and doing so in a way that's sustainable for all concerned."

– CEO, **Heather Bresch**



2019 HIGHLIGHTS

ACCESS

- Global portfolio of **>7,500 products**
- Regulatory approvals for **biosimilars in >85 countries**
- Reached **~5X as many HIV patients per day** around the world as the branded originators combined¹
- **First generic manufacturer to receive WHO prequalification** for daclatasvir to treat hepatitis C
- **~40% of all people treated for HIV** depend on Mylan ARVs every day
- **More than ~60% of the world's HIV+ children** receiving treatment rely on a Mylan medication
- Announced a **global partnership with TB Alliance** for the molecule pretomanid as part of two drug regimens to increase access in many low-income countries
- **12 R&D Centers** across the globe innovating for access
- Supplied into **94 of the 106 Access Countries**³
- **Collaborated with >60 organizations** worldwide on issues of global public health

~62 billion doses sold across **165 countries and territories**, including almost 90% of low- and lower-middle-income countries²

Average price per dose is **18¢ (USD)**

~3,700 PRODUCTS pending approval or in development

ENVIRONMENT

- Increased amount of **recycled waste by 26%**
- Further implemented the **Common Antibiotic Manufacturing Framework** in own operations and notified our active antibiotic suppliers of our alignment with this Framework and expectations of our suppliers
- Continued to enhance our water purification processes across our operations, including **efforts that reduced the amount of rejected water in our Warsaw, Poland, facility by 28%**.
- **Decreased the amount of particulate matter released into the air by 83%** through the installation of new electrostatic precipitator control devices on boilers at our facility in Visakhapatnam, India.

Grew renewable energy consumption by **25%**



PEOPLE

Mylan's diverse workforce reflects the communities where we work as well as the populations we aim to serve. Embracing diverse viewpoints, thinking differently and challenging the status quo all support our ability to understand and meet patients' needs, set new standards in healthcare and deliver better health for a better world.

Global team of **~35,000**

An icon representing a group of 10 people, shown as blue silhouettes of men and women.

- **86% participation** in employee engagement survey
- **77% indicated they are extremely satisfied** with Mylan as a place to work
- **90% of employees** set performance objectives

COMMUNITY

- **Donated hundreds of millions of doses of medicines to organizations** such as AmeriCares, Brother's Brother, Direct Relief International, Dispensary of Hope, Health Partners International of Canada and Heart to Heart International, among others, to assist those in need
- Mylan's programs in health, community welfare and education have **impacted the lives of >11 million people in India over the past five years**

GLOBAL PUBLIC HEALTH

We work hard to give patients around the world a voice and access to affordable medications, through advocacy, shaping policies and sharing knowledge.

- **Advocated for insurance formulary tiering** practices in the U.S. that **would ensure patients pay less out-of-pocket** for lower-cost generics
- **Participated in the WHO** prequalification pilot for cancer biologics
- **Worked with European governments** to establish a waiver **allowing production of generic medicines in the EU** during the brand medicine's patent extension period
- Engaged with the Indian Government to **create and pilot a tuberculosis eradication program**
- **Championed a holistic response to antimicrobial resistance** through access, stewardship appropriate use & surveillance and responsible manufacturing

Visit Mylan.com to read our complete 2019 progress report and learn more about global social responsibility at Mylan. We hope the report offers a useful view of how we've delivered on our mission of providing access from the day we were founded in 1961 until today.

¹Information presented is as of May 4, 2020

²Based on internal estimates and North American and European IQVIA [HIV drug treatment] sales volume for branded originators, which we define as Gilead Sciences, GlaxoSmithKline, Johnson&Johnson, Merck & Co., Bristol-Myers Squibb and Abbvie

³Income groups from the World Bank list of economies (Published July 2019)

⁴As defined by the Access to Medicine Foundation